Relationship between methylation and colonic inflammation in inflammatory bowel disease

Table 1 Patient characteristics n (%)

Patient characteristics	Value
Number of patients	38
Patients with ulcerative colitis (UC)/Crohn’s colitis (CC)	29 (76)/9 (24)
Men	23 (58)
Age (yr): mean ± SD	55.24 ± 14.11
Disease duration (yr): mean ± SD	17.82 ± 8.29
Number of colonoscopies	62
Number of colonoscopies in UC/CC	49 (79)/13 (21)
Disease extension1
Left colitis (UC) or segmentary colitis (CC)	20 (33)
Extensive colitis (UC and CC)	42 (68)
Medication at endoscopy1
Oral 5-ASA	40 (65)
IMM (AZA/6MP)	18 (29)/3 (5)
TNF inhibitor (IFX/ADA)	2 (3)/2 (3)
CRP (mg/dL): mean ± SD	8.25 ± 16.56
Fecal calprotectin (μg/g): mean ± SD	306.5 ± 690.1
Reason for colonoscopy
Endoscopic activity assessment	5 (8)
Dysplasia surveillance	57 (92)
Clinical activity
Active disease	5 (8)
Symptomatic remission	57 (92)
Endoscopic activity
Endoscopic remission	24 (39)
Endoscopic activity	38 (61)
Histological activity and presence of dysplasia
Dysplasia	8 (13)
Acute histological activity	23 (37)
Chronic histological activity	24 (39)
No histological activity	7 (11)
Methylation status
SLIT2 (patients with any methylated sample)	40 (65)
TGFB2 (patients with any methylated sample)	23 (42)

¹As therapy regimens overlapped, the total is 104.7%. ASA: Aminosalicylic acid; CS: Corticosteroids; IMM: Immunomodulators; AZA: Azathioprine; 6MP: 6 mercaptopurine; MTX: Methotrexate; TNF: Tumor necrosis factor; IFX: Infliximab; ADA: Adalimumab.